SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Guggenheim Initiates Coverage On CytomX Therapeutics with Buy Rating, Announces $16 Price Target

Guggenheim initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a Buy rating and a $16 price target.

Benzinga · -

Guggenheim initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a Buy rating and a $16 price target.